There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Icon plc (NASDAQ:ICLR) and Merck & Company (NYSE:MRK) with bullish sentiments.
Icon plc (ICLR)
Icon plc received a Buy rating and a $159 price target from Credit Suisse analyst Erin Wright on October 25. The company’s shares opened today at $134.38.
According to TipRanks.com, Wright is a 4-star analyst with an average return of 7.6% and a 60.6% success rate. Wright covers the Services sector, focusing on stocks such as AmerisourceBergen Corporation, Charles River Labs, and Medpace Holdings.
Currently, the analyst consensus on Icon plc is a Moderate Buy with an average price target of $152, implying a 13.1% upside from current levels. In a report issued on October 25, Robert W. Baird also maintained a Buy rating on the stock with a $158 price target.
.
See today’s analyst top recommended stocks >>
Merck & Company (MRK)
Credit Suisse analyst Vamil Divan maintained a Buy rating on Merck & Company on October 25 and set a price target of $81. The company’s shares opened today at $71.69, close to its 52-week high of $73.49.
According to TipRanks.com, Divan is a 1-star analyst with an average return of -2.3% and a 44.7% success rate. Divan covers the Healthcare sector, focusing on stocks such as Aimmune Therapeutics, Johnson & Johnson, and Portola Pharma.
Currently, the analyst consensus on Merck & Company is a Strong Buy with an average price target of $80.75, a 12.6% upside from current levels. In a report issued on October 12, Barclays also maintained a Buy rating on the stock with a $78 price target.
.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
